{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T05:26:51Z","timestamp":1741411611922,"version":"3.38.0"},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr H. Sci."],"abstract":"<jats:p>Background: To observe and analyse the clinical effects of entecavir on serum hyaluronic acid (HA), laminin (LN), and type IV collagen (IVC) in patients with hepatitis B e-antigen (HBeAG)-positive chronic hepatitis B during clinical treatment.\r\nMethodology: The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy. The clinical curative effects of immune checkpoint inhibitors at different concentrations on diseases were compared from all aspects.\r\nResults: There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P&lt;0.05). The levels of liver function indicators, immune function-related indicators (CD3+, CD4+, CD8+, CD4+\/CD8+, CD4+\/CD8+), and HA, LN and IVC were not statistically different between the two groups before treatment.Conclusion: Entecavir is highly effective in the clinical treatment of HBeAG-positive chronic hepatitis B. However, entecavir + thymalfasin combination therapy can alleviate the clinical symptoms. In this way, liver fibrosis can be prevented in patients with HBeAG-positive chronic hepatitis B, and the clinical curative effect can be enhanced.\r\nKeywords: Entecavir; e antigen-positive chronic hepatitis B; serum hyaluronic acid (HA); laminin (LN); type IV collagen (IVC); clinical outcome analysis.<\/jats:p>","DOI":"10.4314\/ahs.v24i4.6","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T14:30:58Z","timestamp":1741357858000},"page":"38-42","source":"Crossref","is-referenced-by-count":0,"title":["Effect analysis of entecavir on serum hyaluronic acid, laminin and IV collagen in the treatment of hepatitis B E-antigen-positive chronic hepatitis B"],"prefix":"10.4314","volume":"24","author":[{"given":"Jiancheng","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2895","published-online":{"date-parts":[[2025,1,11]]},"container-title":["African Health Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/286028\/269478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/286028\/269478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T14:32:17Z","timestamp":1741357937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/286028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.4314\/ahs.v24i4.6","relation":{},"ISSN":["1729-0503","1680-6905"],"issn-type":[{"value":"1729-0503","type":"electronic"},{"value":"1680-6905","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,11]]}}}